hERG liability classification models using machine learning techniques
暂无分享,去创建一个
[1] Jie Shen,et al. admetSAR: A Comprehensive Source and Free Tool for Assessment of Chemical ADMET Properties , 2012, J. Chem. Inf. Model..
[2] Jun Chen,et al. A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[3] G. Keserü. Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. , 2003, Bioorganic & medicinal chemistry letters.
[4] Woody Sherman,et al. Analysis and comparison of 2D fingerprints: insights into database screening performance using eight fingerprint methods , 2010, J. Cheminformatics.
[5] Scott Boyer,et al. Development, interpretation and temporal evaluation of a global QSAR of hERG electrophysiology screening data , 2007, J. Comput. Aided Mol. Des..
[6] T. Nishikawa,et al. A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors. , 2005, Bioorganic & medicinal chemistry letters.
[7] Yuye He,et al. PaDEL‐DDPredictor: Open‐source software for PD‐PK‐T prediction , 2013, J. Comput. Chem..
[8] Hugo A Katus,et al. The antipsychotic drug chlorpromazine inhibits HERG potassium channels , 2003, British journal of pharmacology.
[9] Jules C Hancox,et al. The hERG potassium channel and hERG screening for drug-induced torsades de pointes. , 2008, Pharmacology & therapeutics.
[10] D. Rampe,et al. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. , 1998, The Journal of pharmacology and experimental therapeutics.
[11] S. Gottlieb. Antihistamine drug withdrawn by manufacturer , 1999, BMJ.
[12] Antranig Basman,et al. HERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study. , 2004, Progress in biophysics and molecular biology.
[13] J. Li,et al. A two-state homology model of the hERG K+ channel: application to ligand binding. , 2005, Bioorganic & medicinal chemistry letters.
[14] Spencer J. Dech,et al. Improved throughput of PatchXpress hERG assay using intracellular potassium fluoride. , 2008, Assay and drug development technologies.
[15] Roy J. Vaz,et al. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. , 2003, Bioorganic & medicinal chemistry letters.
[16] Douglas E. V. Pires,et al. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures , 2015, Journal of medicinal chemistry.
[17] P. Fernandes,et al. Predictive QSAR models development and validation for human ether-a-go-go related gene (hERG) blockers using newer tools , 2014, Journal of enzyme inhibition and medicinal chemistry.
[18] Jules C Hancox,et al. Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes. , 2002, Journal of pharmacological and toxicological methods.
[19] S. Sathiya Keerthi,et al. Improvements to Platt's SMO Algorithm for SVM Classifier Design , 2001, Neural Computation.
[20] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[21] John B. O. Mitchell,et al. Development and Comparison of hERG Blocker Classifiers: Assessment on Different Datasets Yields Markedly Different Results , 2011, Molecular informatics.
[22] W. Crumb,et al. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. , 2002, The Journal of pharmacology and experimental therapeutics.
[23] Robert Preissner,et al. The Catch-22 of Predicting hERG Blockade Using Publicly Accessible Bioactivity Data , 2018, J. Chem. Inf. Model..
[24] Igor V. Tetko,et al. Combinatorial QSAR Modeling of Chemical Toxicants Tested against Tetrahymena pyriformis , 2008, J. Chem. Inf. Model..
[25] T. Danker,et al. Early identification of hERG liability in drug discovery programs by automated patch clamp , 2014, Front. Pharmacol..
[26] A. Tropsha,et al. Beware of q2! , 2002, Journal of molecular graphics & modelling.
[27] D. Wortham,et al. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. , 1993, JAMA.
[28] Alexander Tropsha,et al. Tuning HERG out: antitarget QSAR models for drug development. , 2014, Current topics in medicinal chemistry.
[29] Rita R. Patel,et al. A High-Throughput HERG Potassium Channel Function Assay: An Old Assay with a New Look , 2002, Drug development and industrial pharmacy.
[30] Anthony E. Klon,et al. Machine learning algorithms for the prediction of hERG and CYP450 binding in drug development , 2010, Expert opinion on drug metabolism & toxicology.
[31] CHUN WEI YAP,et al. PaDEL‐descriptor: An open source software to calculate molecular descriptors and fingerprints , 2011, J. Comput. Chem..
[32] Stefan Kramer,et al. Filtered circular fingerprints improve either prediction or runtime performance while retaining interpretability , 2016, Journal of Cheminformatics.
[33] S. Polak,et al. hERG in vitro interchange factors—development and verification , 2009, Toxicology mechanisms and methods.
[34] Yanli Wang,et al. PubChem BioAssay: 2017 update , 2016, Nucleic Acids Res..
[35] Charles H Large,et al. Automated patch clamping using the QPatch. , 2009, Methods in molecular biology.
[36] Chun Wei Yap,et al. Determination of torsade-causing potential of drug candidates using one-class classification and ensemble modelling approaches. , 2012, Current drug safety.
[37] Alexander Tropsha,et al. Best Practices for QSAR Model Development, Validation, and Exploitation , 2010, Molecular informatics.
[38] Tudor I. Oprea,et al. hERG classification model based on a combination of support vector machine method and GRIND descriptors. , 2008, Molecular pharmaceutics.
[39] Alan Finkel,et al. Population Patch Clamp Improves Data Consistency and Success Rates in the Measurement of Ionic Currents , 2006, Journal of biomolecular screening.
[40] Dimitris K Agrafiotis,et al. A QSAR Model of hERG Binding Using a Large, Diverse, and Internally Consistent Training Set , 2006, Chemical biology & drug design.
[41] John C. Platt,et al. Fast training of support vector machines using sequential minimal optimization, advances in kernel methods , 1999 .
[42] Borje Darpo,et al. Clinical Evaluation of QT/QTc Prolongation and Proarrhythmic Potential for Nonantiarrhythmic Drugs: The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 Guideline , 2006, Journal of clinical pharmacology.
[43] Brian B. Goldman,et al. A model for identifying HERG K+ channel blockers. , 2004, Bioorganic & medicinal chemistry.
[44] Victor Guallar,et al. Importance of accurate charges in molecular docking: Quantum mechanical/molecular mechanical (QM/MM) approach , 2005, J. Comput. Chem..
[45] Aarti Desai,et al. Integrated Computational Solution for Predicting Skin Sensitization Potential of Molecules , 2016, PloS one.
[46] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[47] Youyong Li,et al. ADMET evaluation in drug discovery. 12. Development of binary classification models for prediction of hERG potassium channel blockage. , 2012, Molecular pharmaceutics.
[48] Gang Fu,et al. PubChem Substance and Compound databases , 2015, Nucleic Acids Res..
[49] Robert Tibshirani,et al. Classification by Pairwise Coupling , 1997, NIPS.
[50] Matthew Clark,et al. Development and Evaluation of an in Silico Model for hERG Binding , 2006, J. Chem. Inf. Model..
[51] Roberto Todeschini,et al. Handbook of Molecular Descriptors , 2002 .
[52] Woody Sherman,et al. Large-Scale Systematic Analysis of 2D Fingerprint Methods and Parameters to Improve Virtual Screening Enrichments , 2010, J. Chem. Inf. Model..
[53] J C Madden,et al. Integrating (Q)SAR models, expert systems and read-across approaches for the prediction of developmental toxicity. , 2010, Reproductive toxicology.
[54] Leo Breiman,et al. Random Forests , 2001, Machine Learning.
[55] Judith C. Madden,et al. Formation of Structural Categories to Allow for Read‐Across for Teratogenicity , 2009 .
[56] Alexander Tropsha,et al. Pred‐hERG: A Novel web‐Accessible Computational Tool for Predicting Cardiac Toxicity , 2015, Molecular informatics.
[57] Qiuming Gong,et al. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. , 1997, American journal of physiology. Heart and circulatory physiology.
[58] A. Cavalli,et al. Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. , 2002, Journal of medicinal chemistry.
[59] Christopher M. Bishop,et al. Neural networks for pattern recognition , 1995 .
[60] Simon Haykin,et al. Neural Networks: A Comprehensive Foundation , 1998 .
[61] Gerhard F. Ecker,et al. Classification Models for hERG Inhibitors by Counter‐Propagation Neural Networks , 2008, Chemical biology & drug design.
[62] R. Lazzara,et al. Spontaneous Adverse Event Reports of Serious Ventricular Arrhythmias, QT Prolongation, Syncope, and Sudden Death in Patients Treated with Cisapride , 2002, Journal of cardiovascular pharmacology and therapeutics.
[63] Clemens Möller,et al. Automated Electrophysiology Makes the Pace for Cardiac Ion Channel Safety Screening , 2011, Front. Pharmacol..
[64] Noel Southall,et al. Prediction of hERG Liability – Using SVM Classification, Bootstrapping and Jackknifing , 2017, Molecular informatics.
[65] Prabha Garg,et al. Role of breast cancer resistance protein (BCRP) as active efflux transporter on blood-brain barrier (BBB) permeability , 2014, Molecular Diversity.
[66] Karl-Heinz Boven,et al. Micro-Electrode Arrays in Cardiac Safety Pharmacology , 2004, Drug safety.
[67] Alexander Tropsha,et al. Trust, But Verify: On the Importance of Chemical Structure Curation in Cheminformatics and QSAR Modeling Research , 2010, J. Chem. Inf. Model..
[68] Gary R. Mirams,et al. Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment , 2013, Journal of pharmacological and toxicological methods.
[69] R. Friesner,et al. New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. , 2006, Bioorganic & medicinal chemistry.
[70] Jerzy Leszczynski,et al. Consensus QSAR Modeling of Phosphor‐Containing Chiral AChE Inhibitors , 2009 .
[71] Andreas Ebneth,et al. Evaluation of a High-Throughput Fluorescence Assay Method for hERG Potassium Channel Inhibition , 2005, Journal of biomolecular screening.
[72] Simone Brogi,et al. Computational Tool for Fast in silico Evaluation of hERG K+ Channel Affinity , 2017, Front. Chem..
[73] C. January,et al. [3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. , 2001, European journal of pharmacology.